ASCO Abstracts

May 18, 2014
By Applied Clinical Trials

Abstracts related to the conduct of clinical trials, not the actual trials results, from ASCO can be found under the category Health Services Research. Those are then broken down into four areas--

Following is a list of abstracts submitted to ASCO for either presentation at the event or for online only for topics related to clinical trials.

 

Access to Children’s Oncology Group Phase I clinical trials: Racial/ethnic dissimilarities in participation

http://abstracts.asco.org/144/AbstView_144_135104.html

 

Accrual of adolescents and young adults with cancer to eligible clinical trials: A report from the NCIC Clinical Trials Group (NCIC-CTG)

http://abstracts.asco.org/144/AbstView_144_129269.html

 

Discussions about clinical trials among patients with lung and colorectal cancer

http://abstracts.asco.org/144/AbstView_144_125834.html

 

Equity of access: Consent interpretation program at Princess Margaret Cancer Centre (PM) in Canada

http://abstracts.asco.org/144/AbstView_144_132592.html

 

Exclusion of patients with prior cancers from clinical trials: Is this justified?

http://abstracts.asco.org/144/AbstView_144_129732.html

 

FDA breakthrough therapy designation of oncology products: The first-year experience

http://abstracts.asco.org/144/AbstView_144_127621.html

 

Media reporting of practice-changing clinical trials in oncology: A North American perspective

http://abstracts.asco.org/144/AbstView_144_125552.html

 

Social media use amongst oncologists: Results of a national physician survey

http://abstracts.asco.org/144/AbstView_144_133064.html

 

Why is it so difficult to enroll patients in clinical trials?

http://abstracts.asco.org/144/AbstView_144_135223.html

 

Are new drugs more expensive than old ones? Trends in the benefit-adjusted launch prices of anticancer drugs, 1995-2013

http://abstracts.asco.org/144/AbstView_144_127523.html

 

Avoided cost in chemotherapy drugs by patient inclusion in clinical trials

http://abstracts.asco.org/144/AbstView_144_133187.html

 

Developing a predictive model for cancer clinical trial accrual

http://abstracts.asco.org/144/AbstView_144_129783.html

 

 

How much is the pharmaceutical industry's cost of capital for clinical research of novel drugs?

http://abstracts.asco.org/144/AbstView_144_131029.html

 

Hispanic accrual on randomized cancer clinical trials: A call to arms

http://abstracts.asco.org/144/AbstView_144_126803.html

 

Impact of prior cancer on eligibility for lung cancer clinical trials

http://abstracts.asco.org/144/AbstView_144_127107.html

 

A randomized, controlled study comparing NCI’s original and revised informed consent templates

http://abstracts.asco.org/144/AbstView_144_134327.html

 

A tool to help research programs exceed the minimum standards of conducting clinical research

http://abstracts.asco.org/144/AbstView_144_129898.html

 

A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer

http://abstracts.asco.org/144/AbstView_144_129240.html

 

An analysis of cancer-specific Twitter conversations among physicians in 2013

http://abstracts.asco.org/144/AbstView_144_132049.html

 

Are manufacturers targeting smaller patient populations and are they being rewarded for it?

http://abstracts.asco.org/144/AbstView_144_130102.html

 

Are preclinical research findings replicable: An empirical analysis based on EpoR studies in cancer

http://abstracts.asco.org/144/AbstView_144_135167.html

 

Audio visual recording of informed consent: Novel mandatory regulatory compliance for clinical trials in India

http://abstracts.asco.org/144/AbstView_144_134029.html

 

Clinical trial subjects compared to "real world" patients: Generalizability of renal cell carcinoma trials

http://abstracts.asco.org/144/AbstView_144_127782.html

 

Comparison of results between the first and updated reports of phase III clinical trials (RCTs)

http://abstracts.asco.org/144/AbstView_144_128899.html

 

Data quality in clinical trials

http://abstracts.asco.org/144/AbstView_144_128708.html

 

Development of a patient preference assessment tool for cancer patients considering phase I research

http://abstracts.asco.org/144/AbstView_144_127490.html

 

Development of a patient-reported outcome (PRO) measure for assessing non-small cell lung cancer (NSCLC) symptoms in clinical trials: Interim report from the PRO Consortium’s NSCLC Working Group (WG)

http://abstracts.asco.org/144/AbstView_144_130089.html

 

Drug-company–sponsored lectures and physicians' prescribing patterns

http://abstracts.asco.org/144/AbstView_144_125591.html

 

Impact of National Cancer Institute (NCI)-mandated scientific review on protocol development and content

http://abstracts.asco.org/144/AbstView_144_126777.html

 

Impact of the NCI Community Cancer Centers Program (NCCCP) on clinical trial (CT) activities in a community cancer center in rural Nebraska

http://abstracts.asco.org/144/AbstView_144_127658.html

 

Improving cancer clinical trial accrual in Ontario, Canada: The clinical trials infrastructure fund (CTIF) experience

http://abstracts.asco.org/144/AbstView_144_129298.html

 

Improving the patient (pt) experience through physician engagement

http://abstracts.asco.org/144/AbstView_144_131796.html

 

Mobile solution for clinical research documentation

http://abstracts.asco.org/144/AbstView_144_129293.html

 

NCI pilot intervention program to assist accrual for challenging late-phase clinical trials

http://abstracts.asco.org/144/AbstView_144_132024.html

 

Relationship between type of therapeutic intervention and funding source in randomized clinical trials (RCTs) in oncology

http://abstracts.asco.org/144/AbstView_144_132588.html

 

The clinical trial assessment of infrastructure matrix tool (CT AIM) to improve the quality of research conduct in the community

http://abstracts.asco.org/144/AbstView_144_126390.html

 

The road to assessing clinical trial-associated workload

http://abstracts.asco.org/144/AbstView_144_127100.html

 

Which formats for communicating patient-reported outcomes (PROs) work best?

http://abstracts.asco.org/144/AbstView_144_131765.html